ClinicalTrials.gg
CompletedNCT03347058IO & MeUpdated Feb 8, 2023

Immunotherapy & Me

An interventional study of Supportive programming in Cancer, sponsored by Cancer Support Community, Research and Training Institute, Philadelphia. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Cancer Support Community, Research and Training Institute, Philadelphia · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
134
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Immunotherapy \& Me is a pilot study to determine patient and provider needs around immunotherapy treatment, and to determine the most meaningful resources to improve patient outcomes and decrease cost. Specifically, this study aims:

  1. To determine whether layering in customizable resources at the point-of-care that offer healthcare providers care-management tools to give their immunotherapy patients leads to changes in (a) patients' knowledge, attitudes, and health behaviors (including self-reported measures of self-efficacy and empowerment, cancer-related distress, quality of life, and satisfaction with the programs offered) and (b) improved clinical outcomes (including decreased hospital admissions, decreased hospital readmissions, and decreased costs associated with hospitalizations).
  2. To successfully integrate the Immunotherapy \& Me program within oncology practices to provide a model framework for dissemination across other care providers. Once success is demonstrated, a turn-key model of immunotherapy patient support can be expanded to other oncology care systems.
Read the detailed description

As usage and indications for immunotherapy increase, there presents a critical need to identify patient-centered and practice solutions across the continuum of care. Immunotherapy \& Me is an innovative program of customizable resources that seeks to improve the patient experience by supporting the unique needs of both immunotherapy patients and the clinical staff who care for them. The Cancer Support Community (CSC) will implement this operational framework of patient and provider tools at multiple geographically and demographically diverse oncology practices.

The program will include CancerSupportSource® (CSS), a self-administered screening instrument for individuals with cancer that takes approximately 10 minutes to complete and has been validated in 300 English-speaking cancer survivors at CSC affiliates nationwide.The instrument consists of cancer-related problems (physical, social, psychological, emotional and practical) and has been demonstrated to have good internal consistency reliability. Patients are asked to rate the severity of their concerns and if they would like to talk with a staff person and/or receive additional information about their concerns. This information is used to address immediate concerns as well as to develop ongoing educational experiences that are tailored and integrated with their care.

At the end of year one, CSC will evaluate program impact, retool interventions as necessary, and pursue additional funding with the goal of extending services at existing practice sites - and scaling this turnkey model of immunotherapy treatment support.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • immunotherapy
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 134 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Cancer Support Community, Research and Training Institute, Philadelphia is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Receiving immunotherapy as a cancer treatment at a participating pilot site location
  • English- or Spanish-speaking, or having access to a translator

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
134 participants (actual)

Study arms

  • Other
    Supportive programming

    Access to a suite of resources, including digital tools, person-to-person support, and educational resources

    Other: Supportive programming

Interventions

  • OtherSupportive programming

    Access to a suite of resources, including digital tools, person-to-person support, and educational resources

06

What researchers measure

Primary outcomes

  1. CancerSupportSource®

    Cancer-related distress

    Time frame: One year

  2. # of ER visits

    Measured via self-report through a questionnaire developed for this study issued every 30 days

    Time frame: One year

  3. # of hospitalizations

    Measured via self-report through a questionnaire developed for this study issued every 30 days

    Time frame: One year

Secondary outcomes

  1. Self-reported patient confidence in accessing resources

    Measured with a Likert scale (Not at all confident to Extremely confident); assessed every 30 days

    Time frame: One year

07

Study locations

5 sites
  • Catholic Health Initiatives
    Englewood, Colorado 80112, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • OHC
    Cincinnati, Ohio 45242, United States
  • Gettysburg Cancer Center
    Gettysburg, Pennsylvania 17325, United States
  • West Cancer Center
    Germantown, Tennessee 38138, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Mar 2021, 39 months.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 39 months is above that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2017
First posted
Nov 20, 2017
StartActual
Dec 1, 2017
Primary completionActual
Mar 31, 2021
CompletionActual
Mar 31, 2021
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03347058
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Responsible party
Heather Badt, MBA (President, Cancer Support Community, Cancer Support Community, Research and Training Institute, Philadelphia) — Principal investigator
First posted
Nov 20, 2017
Start date
Dec 1, 2017
Primary completion
Mar 31, 2021
Completion
Mar 31, 2021
Last update
Feb 8, 2023

Study contacts

Linda House, RN, BSN, MSM
principal investigator · Cancer Support Community

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion